

Prostatype Genomics' share becomes available for trading in the U.S. on OTCQB Venture Markets

Prostatype Genomics AB ("Prostatype Genomics" or the "Company") announces that the Company's shares will begin trading on the OTCQB Venture Market in the United States on March 13, 2025. Prostatype Genomics' ordinary share will thus be tradable, in parallel to its current Nasdaq First North listing in Stockholm, during U.S. market hours, with a U.S. ticker symbol OTCQB: PGABF and priced in USD to enable access to U.S. broker/dealers and investors.

Joining the OTCQB Venture Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQB, companies must meet financial standards, follow best practice corporate governance and demonstrate compliance with applicable securities laws. Examples of life science related multinational companies trading on the OTCQB Markets are Roche, Sandoz, and CSL Ltd.

"We're excited to begin trading on the OTCQB Market in the U.S. and expand the reach beyond our Nasdaq First North listing. Since we identify U.S. as our most important commercial market, we now welcome more investors to join us as we increase the use of our prognostic genomic test Prostatype® in the U.S. to the benefit of patients with established prostate cancer, their families and relevant healthcare systems. This step should also result in a stronger and more robust trading volume of the Prostatype Genomics share," comments Fredrik Rickman, CEO.

"We are pleased to welcome Prostatype Genomics to the OTCQB® Venture Market," said Joe Coveney, Vice President of OTC Market Group's Corporate Services. "Prostatype Genomics will trade alongside other leading life science and medical device companies that utilize a 'list local, trade global' strategy to leverage their home market filings and disclosures to publicly trade in the US and expand their global investor base."

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our three public markets: OTCQX® Best Market, OTCQB® Venture Market and Pink® Open Market.

Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN and OTC Link NQB are each SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

For more information about the Company, please contact:

Fredrik Rickman, VD
Tel: +46 (0)73-049 77 01
E-mail: fredrik.rickman@prostatypegenomics.com

About Prostatype

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

Certified Adviser

Carnegie Investment Bank AB (publ), +46 73 856 42 65, certifiedadviser@carnegie.se